• 1. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

Comprehensive Guide to 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid (CAS No. 58781-08-1): Properties, Applications, and Market Trends

4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid (CAS No. 58781-08-1) is a versatile heterocyclic compound that has garnered significant attention in pharmaceutical and chemical research. This hexahydroquinoline derivative serves as a crucial building block in medicinal chemistry due to its unique structural features and broad biological activity spectrum. With the increasing demand for novel drug candidates, researchers are actively exploring the potential of this quinoline-based carboxylic acid in developing new therapeutic agents.

The molecular structure of 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid combines a partially hydrogenated quinoline core with a carboxylic acid functionality at the 3-position and a ketone group at the 4-position. This distinctive arrangement contributes to its enhanced solubility compared to fully aromatic quinoline derivatives, making it particularly valuable in formulation development. The compound's molecular weight of 207.22 g/mol and its balanced lipophilicity profile have made it a subject of interest in drug discovery programs targeting various disease pathways.

Recent studies highlight the growing importance of 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid in the development of enzyme inhibitors and receptor modulators. Its structural similarity to biologically active quinoline scaffolds has prompted investigations into its potential as a privileged structure in medicinal chemistry. Researchers are particularly interested in its application for designing anti-inflammatory agents and central nervous system (CNS) active compounds, addressing some of the most pressing healthcare challenges today.

The synthesis of 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid typically involves cyclocondensation reactions of appropriate cyclohexanone derivatives with β-keto esters, followed by selective oxidation steps. Recent advancements in green chemistry approaches have focused on optimizing these synthetic routes to improve yields and reduce environmental impact. These developments align with the pharmaceutical industry's growing emphasis on sustainable synthesis methods and atom economy principles.

In the pharmaceutical market, derivatives of 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid are being explored for their potential in treating neurodegenerative disorders and chronic inflammatory conditions. The compound's ability to serve as a scaffold for multi-target directed ligands makes it particularly valuable in the era of complex disease treatment strategies. Market analysts predict steady growth in demand for this quinoline derivative as research into its therapeutic applications continues to expand.

Quality control of 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid typically involves HPLC analysis and spectroscopic characterization to ensure purity and consistency. The compound's stability profile under various storage conditions has been extensively studied, with recommendations for storage in cool, dry environments protected from light. These quality assurance measures are critical for research applications where reproducible results are essential.

Emerging applications of 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid include its use in material science and coordination chemistry. The compound's ability to act as a chelating ligand has opened new possibilities in catalyst design and functional material development. Researchers are investigating its potential in creating metal-organic frameworks (MOFs) with specific pore structures and surface properties.

From a regulatory perspective, 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid is generally regarded as safe for research purposes when handled according to standard laboratory safety protocols. Its toxicological profile has been studied in preliminary investigations, showing favorable characteristics for further development. However, as with all chemical substances, appropriate personal protective equipment (PPE) should be used when handling the compound in laboratory settings.

The future outlook for 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid appears promising, with ongoing research exploring its potential in drug discovery and material innovation. As synthetic methodologies continue to improve and biological investigations uncover new applications, this compound is likely to maintain its position as an important chemical building block in multiple scientific disciplines. The growing body of literature referencing this compound underscores its significance in contemporary chemical research.

For researchers and industry professionals seeking high-quality 4-Oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid, it's essential to source the material from reputable suppliers who can provide comprehensive analytical data and certificates of analysis. The compound's purity and consistency are critical factors that can significantly impact research outcomes and development timelines in pharmaceutical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)